Mirum Pharmaceuticals, Inc. (MIRM)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Livmarli Revenue	441.15M	360.01M	213.30M
Bile Acid Medicines Revenue	176.92M	161.31M	123.11M
Total Product Revenue, Net	618.07M	521.31M	336.41M
License and Other Revenue	-	-	479.00K
Revenue (Total)	618.07M	521.31M	336.89M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
License and Other Revenue	-	-	479.00K
United States - Product Revenue	485.36M	401.55M	274.17M
Rest of the World - Product Revenue	132.71M	119.77M	62.24M
Revenue (Total)	618.07M	521.31M	336.89M

Data Source: Fiscal.ai Last updated: Aug 5, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error